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Genome-wide association studies have identified multiple risk 
variants and loci that show robust association with schizo-
phrenia. Nevertheless, it remains unclear how these variants 
confer risk to schizophrenia. In addition, the driving force 
that maintains the schizophrenia risk variants in human gene 
pool is poorly understood. To investigate whether expres-
sion-associated genetic variants contribute to schizophrenia 
susceptibility, we systematically integrated brain expression 
quantitative trait loci and genome-wide association data of 
schizophrenia using Sherlock, a Bayesian statistical frame-
work. Our analyses identified ZNF323 as a schizophrenia 
risk gene (P = 2.22 × 10–6). Subsequent analyses confirmed 
the association of the ZNF323 and its expression-associated 
single nucleotide polymorphism rs1150711 in independent 
samples (gene-expression: P  =  1.40 × 10–6; single-marker 
meta-analysis in the combined discovery and replication 
sample comprising 44 123 individuals: P = 6.85 × 10−10). We 
found that the ZNF323 was significantly downregulated in 
hippocampus and frontal cortex of schizophrenia patients 
(P = .0038 and P = .0233, respectively). Evidence for pleio-
tropic effects was detected (association of rs1150711 with 
lung function and gene expression of ZNF323 in lung: 
P = 6.62 × 10–5 and P = 9.00 × 10–5, respectively) with the 
risk allele (T allele) for schizophrenia acting as protective 
allele for lung function. Subsequent population genetics 
analyses suggest that the risk allele (T) of rs1150711 might 
have undergone recent positive selection in human popula-
tion. Our findings suggest that the ZNF323 is a schizo-
phrenia susceptibility gene whose expression may influence 
schizophrenia risk. Our study also illustrates a possible 
mechanism for maintaining schizophrenia risk variants in 
the human gene pool.
ZNF323 is a novel schizophrenia risk gene
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Introduction
Schizophrenia is a multifactorial and polygenic mental 
disorder with strong genetic heterogeneity and high heri-
tability.1,2 To date schizophrenia remains an evolutionary-
genetic paradox as fecundity of schizophrenia patients 
(ie, strongly negative fitness) seemingly contradicts its 
stable prevalence of approximately 1% across all human 
cultures.3–5 One potential explanation for this conundrum 
suggests recent positive selection based on compensa-
tory effects on other human traits as (among others) the 
driving force in maintaining schizophrenia risk loci in 
the gene pool.4–6 In line with this hypothesis, recent stud-
ies have identified pleiotropic effects of schizophrenia risk 
variants.7,8
Multiple promising risk variants and loci for schizo-
phrenia have been identified by genome-wide association 
studies (GWAS) of schizophrenia.1,9–11 Nevertheless, how 
these variants confer risk to schizophrenia remains elu-
sive. Moreover, the identified susceptibility variants only 
explain a small fraction of the disease variance. A recent 
study has suggested that more than 8000 common loci are 
involved in the etiology of schizophrenia,11 thus indicat-
ing that many common risk loci with potentially small 
effect sizes and/or with infrequent risk alleles are still to 
be detected.
Although more schizophrenia risk loci remain to be 
identified, accumulating evidence strongly suggests that 
changes in gene expression rather than alterations in protein 
function play a key role in the pathogenesis of schizophre-
nia.12–14 Accordingly, recent studies have used integrative 
strategies to combine results from association studies and 
gene expression analyses.15,16 The successful identification 
of schizophrenia susceptibility genes by these integrative 
methods supports the important roles of gene expression 
alteration in the pathogenesis of schizophrenia. However, 
currently there is no study that systematically integrated 
brain expression quantitative trait loci (eQTL) data and 
GWAS of schizophrenia to identify the potential schizo-
phrenia risk genes.
In this study, we followed an integrated data analysis 
approach using Sherlock17 and analyzed eQTL from normal 
human brain samples18 together with association data from 
a large GWAS for schizophrenia.11 To further characterize 
the potential role of our identified loci in schizophrenia eti-
ology, we followed up and refined our results in independent 
gene expression and large-scale genetic datasets. Moreover, 
we subsequently tested for pleiotropic effects (ie, a simulta-
neous effect of our identified risk loci on other human traits) 
and tried to shed light on the potential presence of positive 
natural selection (as a consequence of compensatory effects 
on the traits implicated by the pleiotropic analyses).
Methods
Sherlock integration analysis
Considering that most of the disease-associated vari-
ants identified by recent GWAS are located in noncod-
ing regions,19 it is likely that these risk variants affect gene 
expression rather than protein function. To infer genes 
whose expression changes may contribute to the etiol-
ogy of complex diseases, He et al17 developed a statistical 
framework (named Sherlock) to identify the potential dis-
ease-associated genes through matching eQTL and single-
nucleotide polymorphism (SNP) associations from GWAS. 
The underlying assumption is that the expression level of 
a specific gene(s) may influence the risk of a disease (eg, 
schizophrenia). Therefore, genetic variation (both in cis, ie, 
close to the gene, and in trans, ie, distant to the gene or on 
different chromosomes) that perturbs gene expression may 
affect the risk of this disease. For a given gene there may 
be several variants (expression-associated SNPs [eSNPs]) in 
the genome that act together to regulate the expression level 
of this gene. Genetic variation at these eSNPs would influ-
ence the expression level of this gene, which in turn might 
affect schizophrenia susceptibility. Hence, cumulative evi-
dence from both eQTL and GWAS findings is indicative of 
association with schizophrenia. Sherlock first searches for 
all eSNPs of each gene using the whole genome eQTL data 
from the human frontal cortex.18 For each eSNP, Sherlock 
will then evaluate its association with schizophrenia using 
genome-wide association (GWA) data of schizophrenia.11 
There are three different scenarios: (1) If the eSNP of a spe-
cific gene is also associated with schizophrenia in GWAS, a 
positive score would be given; (2) If the eSNP of this gene is 
not associated with schizophrenia, a negative score would be 
assigned; and (3) association only in GWAS (ie, non-eSNPs) 
does not alter the score. The total score of a gene increases 
along with the increase of the number of SNPs with com-
bined evidence (SNPs that are associated with schizophre-
nia and expression). Finally, Sherlock identifies gene-disease 
associations through matching genetic signatures of gene 
expression traits to that of disease.17 Statistical inference was 
performed using Bayes statistical framework17 and Bayes 
factor (BF, the probability of the observed data under a 
specific model) of each SNP was calculated separately. For 
each gene, Sherlock computes individual logarithm of BF 
(LBF) for each SNP pair in the alignment, and the sum of 
these constitutes the final LBF score for the gene. The value 
of the LBF score of a gene reflects the strength of evidence 
(ie, a larger LBF represents higher probability that this gene 
is associated with the disease). Sherlock utilizes moderately 
associated cis and trans eSNPs (without introducing many 
false signals) instead of solely focusing on eSNPs that meet 
stringent cutoff criteria for both eQTL and GWAS results. 
P values of the BFs were calculated with simulation using 
Bayes/non-Bayes compromise.20 False discovery rate (FDR) 
was calculated using Benjamini–Hochberg procedure21 at P 
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threshold of 10–5. More detailed information about the sta-
tistical model and the underlying algorithm is provided in 
the original paper by He et al.17
Brain Expression (eQTL) Data
Considering that schizophrenia is a mental disorder that 
mainly originates from abnormal brain function, it is rea-
sonable to assume that the most appropriate tissue for an 
integrative identification of schizophrenia risk genes is the 
human brain. Therefore, we used brain expression data 
(human prefrontal cortex [PFC]) from a previous study 
on 193 neuropathologically normal human brain sam-
ples.18 All individuals enrolled in this study were of self-
reported European ancestry. Genotyping was performed 
on an Affymetrix Human Mapping 500K Array Set and 
expression profiles were identified using an Illumina 
HumanRefseq-8 Expression BeadChip. Cis eSNPs were 
defined as SNPs situated within the transcript of the 
respective gene or within 1 Mb of either the 5′ or the 3′ 
end of the transcript. More information about statistical 
analyses and procedures is provided in the original study.18
Schizophrenia GWAS Data
We used summary statistics from a large-scale schizophrenia 
GWAS.11 In brief, the study represents a meta-analysis of a 
recent schizophrenia GWAS from the Psychiatric Genomics 
Consortium (PGC), hereafter referred to as “PGC1,”9 and 
independent data from a Swedish schizophrenia GWAS 
(“SWE”).11 The study comprised a total of 13 833 schizo-
phrenia cases and 18 310 controls (“SWE + PGC1”)11 
and identified 22 risk loci for schizophrenia. Most of the 
subjects were of European ancestry. DNA was extracted 
from peripheral blood and samples were genotyped using 
Affymetrix (5.0 and 6.0) and Illumina OmniExpress chips 
according to the manufacturers’ instructions. The associa-
tion analysis was first performed in SWE samples (5001 
cases and 6243 controls) with PLINK22 using imputed SNP 
dosages and the principal components as covariates. Then 
the results from SWE samples were meta-analyzed with 
the results from PGC1 (8832 cases and 12 067 controls) 
using an inverse-weighted fixed-effects model.23 Genome-
wide genetic association information (P values of a total 
of 9 898 078 SNPs) from SWE + PGC1 was used as input 
in this study. Detailed information about sample ascertain-
ment, diagnosis, genotyping quality control, and statistical 
analyses can be found in the original study and PGC web-
site (https://pgc.unc.edu).11
Replication and Refinement of Gene Expression Results
Four well-characterized expression databases were used 
to follow-up on the gene expression results that contrib-
uted to identification of ZNF323 as our top schizophre-
nia risk gene. In addition to the replication, the follow-up 
comprised a deeper characterization of gene expression 
patterns for ZNF323 in the brain (eg, healthy individuals 
vs schizophrenia patients) and identification of addi-
tional eSNPs of ZNF323.
A brief  description of  the gene expression resources is 
provided below; more detailed information can be found 
in the original studies.24–27 (1) BrainCloud.24 BrainCloud 
contains genetic information and whole transcriptome 
expression data from postmortem dorsolateral PFC 
(DLPFC) of  269 normal human subjects (ie, without 
neuropathological or neuropsychiatric diagnosis). The 
data in BrainCloud is aimed at exploring temporal 
dynamics and genetic control of  transcription in the 
DLPFC across the lifespan, ie, from fetal development 
through ageing. (2) The Genotype-Tissue Expression 
project (GTEx).25 Compared with BrainCloud, which 
focuses on the DLPFC, the GTEx contains information 
at the level of  both genetic variation and gene expression 
from a diverse set of  human tissues including different 
brain regions. So far, 3797 tissues from 150 postmor-
tem donors have been collected and subsequently ana-
lyzed using a RNA sequencing (RNA-seq)–based gene 
expression approach. (3) The Stanley Neuropathology 
Consortium Integrative Database (SNCID).26 The 
SNCID contains gene expression information for dif-
ferent brain regions (including hippocampal tissue and 
PFC) of  61 individuals, including 20 bipolar disorder 
patients, 20 schizophrenia cases, and 21 healthy controls. 
(4) The Human Brain Transcriptome (HBT) database.27 
The HBT comprises the transcriptome of 16 regions: the 
cerebellar cortex, mediodorsal nucleus of  the thalamus, 
striatum, amygdala, hippocampus, and 11 areas of  the 
neocortex.
Replication and Refinement of GWAS Results
In order to replicate the GWAS results that contributed 
to our integrated results from the discovery step and 
in order to follow-up on newly identified eSNPs in the 
eQTL replication step, we utilized four well-characterized 
GWAS datasets:
(1) Independent Samples From the German MooDS SCZ 
Working Group.28 This sample contained 1332 schizo-
phrenia cases and 866 controls. It represents the nonover-
lapping part (PGC, “SGENE-Bonn”) of the MooDS 
SCZ Consortium sample that has been described in 
detail in study of Priebe et al.28 Thus, there is no over-
lap between individuals from our German replication 
sample and subjects in the discovery step from the Ripke 
et  al study (PGC1 + SWE).11 The study was approved 
by the ethics committees of all study centers and written 
informed consent was obtained from all participants prior 
to inclusion. All patients were recruited from consecutive 
admissions to psychiatric inpatient units and of German 
descent according to self-reported ancestry. Venous 
blood samples were obtained from all participants and 
genotyping was performed using Illumina’s BeadChips, 
including HumanHap550v3, Human610-Quadv1, and 
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Human660W-Quad. More detailed information on sam-
ple description, genotyping, quality control of controls 
utilized in this study can be found in the paper of Muglia 
et al.29
(2) Independent Family–Based Replication Sample From 
a Recent Study.30 This sample consisted of 6298 indi-
viduals (including 3286 schizophrenia cases) from 1811 
nuclear families. There were three independent family–
based samples included in this family-based replication 
sample, the European family–based sample (2740 indi-
viduals, 794 families, and 1420 schizophrenia cases), the 
Asian family–based sample (2296 individuals, 579 fami-
lies, and 1222 schizophrenia cases), and the African fam-
ily–based sample (1262 individuals, 438 families, and 644 
schizophrenia cases). Because three subsamples included 
in this family-based samples, genetic association analysis 
in nuclear families was performed within each ancestral 
group using UNPHASED program31 to minimize the risk 
of population stratification effects. The results were then 
combined to obtain an overall P value. All of the individ-
uals from this family-based sample do not overlap with 
the subjects from the discovery step of Ripke et al (PGC1 
+ SWE sample11). More detailed information about sam-
ple description (recruitment of schizophrenic patient and 
healthy controls, diagnosis), genotyping, quality control, 
population stratification analysis, and statistical analysis 
can be found in the original paper.30
(3) Two Independent Danish GWAS Datasets.32 This 
sample composed of two datasets with a total of 1735 
schizophrenia cases (876 and 859, respectively) and 
1749 controls (871 and 878, respectively). There is no 
overlap between individuals from our Danish replica-
tion sample and subjects in the discovery step from 
the Ripke et  al study (“PGC1 + SWE”11). A  detailed 
description of the Danish study samples is provided 
elsewhere.32 In brief, the samples used in this study here 
comprised the discovery step of a Danish schizophrenia 
GWAS32 and a larger part of its initial replication sam-
ples that was in the meantime genotyped using Illumina’s 
HumanCoreExome BeadChip. All involved samples 
were initially employed in two matched case-control 
designs (see above) and identified through the Danish 
Psychiatric Central Register.33 The DNA was accessed 
through the Danish Newborn Screening Biobank34 and 
was extracted from dried blood spots using Extract-N-
Amp Blood PCR kit (Sigma Aldrich, Seelze, Germany) 
and subsequently whole genome-amplified in triplicates 
using the RepliG kit (Qiagen, Venlo, The Netherlands).35 
Subsequent genotyping for the first sample (discovery) 
was performed using Illumina’s Human 610-quad bead-
chips (Illumina) and the second sample as described 
above. Diagnosis of all schizophrenia cases was based on 
ICD-10-DCR (The ICD-10 Classification of Mental and 
Behavioural Disorders Diagnostic Criteria for Research; 
F20). Summary statistics of all four studies (comprising a 
total of 6353 schizophrenia patients) were meta-analyzed 
using PLINK.22 There is no overlap between individuals 
from our replication samples and subjects in the PGC1 
+ SWE.
Pleiotropic Effects Analyses of the Identified Risk Loci
The National Human Genome Research Institute’s 
(NHGRI) GWAS Catalog36,37 comprises a curated list of 
results from all GWAS in humans to date (as of April 16, 
2014, 1902 publications and 13 156 SNPs are listed) and 
therefore provides a valuable resource to study pleiotropic 
effects. We first explored whether ZNF323 and its eSNPs 
were associated with other traits. We next investigated 
whether the observed associations of eSNPS of ZNF323 
with schizophrenia and lung function could have been the 
result of confounding. More detailed information about 
the pleiotropy analyses can be found in supplementary 
methods.
Bioinformatic Analysis and Functional Prediction of 
rs1150711
We examined the potential chromatin interactions 
between the genomic region containing rs1150711 and 
its neighboring regions using the Hi-C chromatin inter-
actions (from the study of  Dixon et  al).38 In addition, 
we performed bioinformatic analyses to predict the 
potential functional consequences of  rs1150711 using 
Regulome DB (http://www.regulomedb.org).39 Multiple 
types of  data (eg, ChIP-seq, DNase-seq, and eQTLs) 
from the Encyclopedia of  DNA Elements (ENCODE) 
project40 and other sources were integrated into the 
Regulome DB to estimate the possible function of  can-
didate SNPs.
Population Genetic Analyses
We utilized different approaches to investigate whether 
our top eSNPs and/or ZNF323 underwent recent posi-
tive selection in human populations. (1) Analysis of 
extended haplotype homozygosity (EHH): Haplotypes 
with unusually high EHH and high population fre-
quency suggest recent positive selection that has driven 
rapid increase in frequency of  new variants or haplo-
types in the population.41 We used Sweep,41 the rehh 
package in R42 and data from the HapMap project43 
and the 1000 Genomes project44 to estimate the EHH 
of  the region surrounding the eSNP of  ZNF323. (2) 
Calculation of integrated haplotype score (iHS): The 
iHS derived from EHH45 represents an indicator of 
recent positive selection. Large negative or positive val-
ues indicate unusually long haplotypes (that carry the 
derived or the ancestral allele), whereas small values 
of  iHS indicates no obvious recent positive selection. 
An |iHS| > 2.0 indicates a significant (corresponding to 
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P < .05) positive selection signal.45 We used Haplotter45 
and data from the HapMap project43 and the 1000 
Genomes project44 to calculate iHS. (3) The Composite 
of Multiple Signals (CMS) test46: The CMS integrates 
information from both EHH and iHS (together with 
Fst and two additional frequency-spectra–based tests) 
and is thought to have greater power compared with 
the two aforementioned tests. (4) Level of allelic differ-
entiation in different populations (Fst): Alleles, which 
experienced positive selection in a specific population 
or geographic region, have larger allelic differentiation 
(frequency differences) between populations compared 
with neutrally evolved alleles. We compared allele fre-
quencies of  our eSNPs in global populations by using 
genotype information from the Human Genome 
Diversity Project (HGDP) selection browser (http://
hgdp.uchicago.edu/cgi-bin/gbrowse/HGDP/),47 which 
contains the allele frequency data of  53 worldwide pop-
ulations. To perform neutrality tests (including Tajima’s 
D,48 Fu and Li’s D49 tests, and Fay and Wu’s H test50), 
we obtained sequencing data (including 99 Europeans, 
103 Han Chinese, and 108 Africans) encompassing the 
entire ZNF323 gene (chr6:28,292,515-28,304,152, hg19) 
from the 1000 Human Genomes Project.44 Neutrality 
tests were carried out using DnaSP software (version 
5).51 Fst (a measure of  population differentiation) of 
rs1150711 was calculated using the method described in 
study of  Cheng et al.52 For clarity, a workflow diagram 
illustrating these analyses is provided in supplementary 
figure S1.
Results
Sherlock Integrative Analyses (Discovery Step) 
Identified ZNF323 as a Novel Schizophrenia Risk Gene
Through systematic integration of  brain eQTL18 and 
SNP associations (a total of  9 898 078 SNPs) from a 
large GWAS of schizophrenia (PGC1 + SWE, includ-
ing 13 833 schizophrenia cases and 18 310 controls)11 
using Sherlock17 (see “Methods” section and supple-
mentary figure S1), ZNF323 (6p22.1) showed the most 
significant association with schizophrenia (LBF = 7.09, 
Psher = 2.2 × 10
–6, FDR = 3.69 × 10–3) (table 1). One eSNP 
of ZNF323 (rs2859365) showed significant associa-
tion with ZNF323 expression (PeQTL  =  5.90 × 10
–8) and 
suggestive evidence for association with schizophrenia 
(PGWAS = 2.07 × 10
–7) (table 2). Homozygous carriers of 
the risk allele (A) of  rs2859365 showed a reduced expres-
sion of  ZNF323. Results for all genes with LBF > 5.0 
and P-value < 10–4 are listed in table 1. Supporting SNPs 
for top predicted genes for schizophrenia are listed in 
supplementary table S1.
Table 1. Integrative Analysis (Sherlock) of Schizophrenia GWAS and Brain eQTL Reveals That ZNF323 Had the Most Significant 
Association With Schizophrenia
Gene symbol LBFa P-valueb Supporting SNPc (cis or trans) PeQTL
d PGWAS
e FDRf
ZNF323 7.09 2.22 × 10–6 rs2859365 (cis) 5.90 × 10–8 2.07 × 10–7 3.69 × 10–3
NAPSA 7.04 2.22 × 10–6 rs10226475 (trans) 6.74 × 10–6 2.02 × 10−10 3.69 × 10–3
LOC378135 6.76 2.22 × 10–6 rs134169 (trans) 6.17 × 10–6 2.50 × 10–5 3.69 × 10–3
EPB41L2 6.66 2.22 × 10–6 rs7752195 (trans) 1.17 × 10–6 1.82 × 10–5 3.69 × 10–3
GLT8D1 5.83 4.43 × 10–6 rs2240920 (cis) 5.22 × 10–16 7.30 × 10–6 7.35 × 10–3
RCN1 5.83 4.43 × 10–6 rs3800917 (trans) 6.56 × 10–7 6.27 × 10−10 7.35 × 10–3
ALMS1 5.56 1.11 × 10–5 rs6753344 (cis) 1.37 × 10–9 5.00 × 10–5 1.84 × 10–2
EIF4A2 5.39 1.11 × 10–5 rs17002034 (trans) 4.00 × 10–7 1.40 × 10–6 1.84 × 10–2
MPV17L2 5.30 1.11 × 10–5 rs7752195 (trans) 1.54 × 10–6 1.82 × 10–5 1.84 × 10–2
LSAMP 5.13 1.11 × 10–5 rs4976976 (trans) 4.53 × 10–7 6.23 × 10–6 1.84 × 10–2
CSNK2B 5.11 1.11 × 10–5 rs707939 (cis) 5.35 × 10–6 8.23 × 10–5 1.84 × 10–2
PLCD4 5.09 1.55 × 10–5 rs2160567 (trans) 7.40 × 10–7 8.29 × 10–6 2.57 × 10–2
aLBF (Log Bayes Factors for each gene) evaluates whether the combined evidence from GWAS and expression studies support a gene 
being associated with schizophrenia. For example, a LBF of 4.6 means that the alternative hypothesis (associated with Schizophrenia) is 
100 times (exp[4.6] = 100) more likely than the null hypothesis (no association). High Bayes factors tend to correlate with low P-values. 
Several eSNPs may be associated with the expression of a gene. For each of these eSNP, if  it is also associated with schizophrenia in 
GWAS, a positive score would be given; otherwise, a negative score. Association only in GWAS (ie, non-eSNPs) does not alter the score. 
The total score of a gene increases with the number of SNPs with combined evidence (SNPs that are associated with schizophrenia and 
expression). For each gene, Sherlock computes individual LBFs for each SNP pair in the alignment, and the sum of these constitutes the 
final LBF score for the gene.
bP-value from Sherlock integrative analysis.
cSNP with the highest LBF score.
dP-value for eQTL SNP from the gene expression study.18
eP-value for eQTL SNP from the GWAS of schizophrenia.11
fFDR was calculated at P = 10–5 threshold. It should be noted that some genes with different LBF scores may have the same P-values. 
This is because that Sherlock computes P-values by finite permutations. If  the number of permutation is not extremely high, it is possible 
that two different values of LBF correspond to the same P-values (their rankings are the same). Genes with LBF > 5.0 and P-value < 
10–4 are listed.
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Replication and Refinement of eQTL and GWAS 
Results for ZNF323
To replicate our results, we tested the association between 
rs2859365 and expression of ZNF323 in an independent 
gene expression dataset, the BrainCloud.24 The result 
confirmed the significant association of rs2859365 with 
ZNF323 expression in the PFC (P  =  1.60 × 10–7) (fig-
ure  1A). Again, homozygous risk allele carriers have a 
reduced ZNF323 expression compared with the nonrisk 
allele individuals (figure 1A).
We further tested whether rs2859365 is associated with 
ZNF323 expression in brain regions other than the PFC in a 
third independent expression dataset (the GTEx).25 We found 
that rs2859365 showed significant association with ZNF323 
expression in the hippocampus (P = 5.0 × 10–3) (figure 1B), 
the caudate basal ganglia (P = 2.0 × 10–2) (figure 1C), and 
Fig. 1. rs2859365 and rs1150711 are significantly associated with ZNF323 expression in human prefrontal cortex (PFC). (A) rs2859365 is 
significantly associated with the expression level of ZNF323 in the PFC of normal human subjects (n = 268) across the lifespan (P = 1.60 × 10–7).  
The individuals with AA genotype have lower ZNF323 expression level. (B–D) rs2859365 is also significantly associated with the ZNF323 
expression in the hippocampus (B), the caudate basal ganglia (C), and the substatia nigra (D). (E) rs1150711 is significantly associated with the 
expression level of ZNF323 in the PFC of normal human subjects (n = 268) across the lifespan (P = 1.40 × 10–6). Individuals carrying the risk 
rs1150711 TT genotype (risk allele: T allele) have significant lower ZNF323 expression level than CC genotype carriers. (F–H) rs1150711 is also 
significantly associated with the ZNF323 expression in the hippocampus (F), the caudate basal ganglia (G), and the substatia nigra (H).
Table 2. Multiple eSNPs of ZNF323 Are Significantly Associated With Schizophrenia in the PGC1 + SWE Sample (13 833 Cases and 
18 310 Controls)
Gene symbol SNP ID Chromosome: Position eQTL P valuea GWAS P valueb
ZNF323 rs1150711 6:28208535 1.40 × 10–6 2.76 × 10–9
rs2859365 6:28391465 1.60 × 10–7 2.07 × 10–7
rs853684 6:28294550 9.52 × 10–7 4.73 × 10–7
rs213240 6:28315875 2.89 × 10–6 5.40 × 10–7
rs1997660 6:28269663 9.99 × 10–6 6.23 × 10–8
rs853693 6:28282648 9.99 × 10–6 6.04 × 10–8
rs12214383 6:28223731 1.48 × 10–5 2.56 × 10–6
rs916403 6:28408258 4.63 × 10–5 3.24 × 10–6
rs9380069 6:28203300 4.76 × 10–5 2.31 × 10–7
rs9461446 6:28227633 5.77 × 10–6 0.78
rs9461448 6:28263721 3.87 × 10–5 0.83
Boldface letters were used to highlight the genetic variants that we are interested in.
aeQTL P value shows the association significance between this SNP and ZNF323 expression level in human brain (Brain eQTL data is 
from the study of Colantuoni et al24).
bGWAS P value represents the association significance between this SNP and schizophrenia (Based on association data from the PGC1 + 
SWE samples, included 13 833 schizophrenia cases and 18 310 controls11).
1300
X.-J. Luo et al
the substantia nigra (P = 6.0 × 10–4) (figure 1D). Consistent 
with the findings from the PFC, we found that homozygous 
risk allele carriers for rs2859365 did show a reduced expres-
sion of ZNF323 in the hippocampus, caudate basal ganglia 
and the substantia nigra (figures 1B–D).
Similar to our validations on the eQTL results, we 
also attempted to replicate the GWAS signal (PGC1 + 
SWE study) for rs2859365 (P = 2.07 × 10–7) in indepen-
dent schizophrenia datasets. Meta-analysis of six inde-
pendent datasets comprising 6353 schizophrenia patients 
and 5618 controls yielded a P-value of .111 (overall com-
bined P-value for PGC1 + SWE and the replication was 
1.40 × 10–7) with the same effect allele (A) and effect direc-
tion as in the PGC1 + SWE study (table 3).
Evidence for Additional eSNPs of ZNF323
Considering that the expression of ZNF323 is signifi-
cantly associated with schizophrenia, we hypothesized that 
other eSNPs of ZNF323 might also be associated with 
schizophrenia. We therefore identified the other eSNPs of 
ZNF323 by using BrainCloud.24 Only eSNPs with a P-value 
less than 1.0 × 10–4 were considered. In total, we identified 
11 SNPs that showed an association with ZNF323 expres-
sion at the aforementioned P-value threshold (table 2). We 
further investigated the linkage disequilibrium (LD) pat-
tern among the 11 eSNPs in Europeans based on geno-
type data from the 1000 Genomes project.44 Our analysis 
revealed two LD blocks (supplementary figure S2) with the 
initial lead eSNP rs2859365 (that was identified through the 
integrated analysis) located in haplotype block 2. Among 
the eSNPs in haplotype block 1, rs1150711 showed asso-
ciation with ZNF323 expression in the BrainCloud dataset 
(P = 1.40 × 10–6) (figure 1E) and reached genome-wide sig-
nificance in the PGC1 + SWE GWAS data (P = 2.76 × 10–
9) (table 2). Further investigation of rs1150711 in the GTEx 
expression dataset revealed that rs1150711 is significantly 
associated with ZNF323 expression in the hippocampus 
(P = 6.0 × 10–4), the caudate basal ganglia (P = 2.0 × 10–3), 
and the substantia nigra (P = 3.0 × 10–3) (figures 1F–H). 
Consistent with results of rs2859365, homozygous risk 
allele (T) carriers have a reduced ZNF323 expression 
compared with the nonrisk allele individuals (figures 
1E–H). Additional support was gained from meta-analy-
sis of our independent replication samples for rs1150711 
(P = 0.037; overall combined P-value for PGC1 + SWE 
and the replication was 6.85 × 10−10) (table 3). To explore 
if rs1150711 is a cis or trans eQTL of ZNF323, we exam-
ined the genomic location of rs1150711 and ZNF323 and 
found that rs1150711 is located in ~84-kb downstream of 
ZNF323. As rs1150711 and ZNF323 are located closely on 
same chromosome, according to the criteria described in 
previous papers,17,53–55 rs1150711 is a cis eQTL of ZNF323.
SNP rs1150711 is located in the MHC region, consider-
ing the high LD among genes in this region, it is possible 
that the association between rs1150711 and schizophre-
nia is attributed to another causal variant that is highly 
linked with rs1150711. To test if  there are SNPs that are 
Table 3. Discovery and Replication Results of rs1150711 and rs2859365 in Schizophrenia Samples Comprising a Total of 44 123 
Individuals
SNP ID Sample (cases)
Allelea
ORb P valuecEA OA
rs2859365 European sample (1420) A G 1.030 0.659
Asian sample (1222) A G 1.077 0.266
African sample (644) A G 1.008 0.941
German sample (1332) A G 1.155 0.025
Danish sample 1 (876) A G 0.964 0.609
Danish sample 2 (859) A G 1.027 0.702
Combined replication (6 353) A G 1.047 0.111
PGC1 + SWE (13 833) A G 1.095 2.07 × 10–7
Overall combined (20 186) A G 1.082 1.40 × 10–7
rs1150711 European sample (1420) T C 1.109 0.140
Asian sample (1222) T C 1.057 0.413
African sample (644) T C 1.134 0.329
German sample (1332) T C 1.209 0.007
Danish sample 1 (876) T C 0.920 0.289
Danish sample 2 (859) T C 1.009 0.908
Combined replication (6353) T C 1.068 0.037
PGC1 + SWE (13 833) T C 1.119 2.76 × 10–9
Overall combined (20 186) T C 1.105 6.85 × 10−10
Boldface letters and italics were used to highlight the genetic variants that we are interested in.
aEA: effect allele, OA: other allele.
bOR (odds ratio) is based on effect allele.
cTwo-tailed P values. Combined analyses are based on a fixed effects meta-analysis of individual study results.
1301
ZNF323 Is a Novel Schizophrenia Risk Gene
in high linkage disequilibrium with rs1150711, we con-
ducted LD analysis using genotype data from the 1000 
Genomes project.44 LD analysis revealed that 7 SNPs are 
highly linked (r2 > 0.80) with rs1150711 (supplementary 
figure S3 and supplementary table S2). We investigated 
the association between these SNPs and schizophrenia 
and found that rs1150711 showed the most significant 
association with schizophrenia (supplementary figure S3 
and supplementary table S2). Collectively, these results 
suggest that SNP rs1150711 may represent an indepen-
dent schizophrenia-associated variant. However, given 
the degree of LD in this region (there are many SNPs 
showed moderate LD (r2 > 0.6) with rs1150711), we could 
not completely rule out the potential effect of synthetic 
association.
Pleiotropic Analyses for rs1150711
Our above data showed a significant association between 
rs1150711 and ZNF323 expression in human brain tis-
sues. To further explore if  rs1150711 is also associated 
with expression of other genes adjacent to ZNF323, we 
investigated the pleiotropic effects of rs1150711 using 
BrainCloud24 and NCBI eQTL browser (which contains 
well-characterized brain eQTL dataset).56 Both of these 
two datasets used brain tissues from the frontal cortex, 
a region associated with schizophrenia.57,58 We found 
that rs1150711 showed the most significant association 
with ZNF323 expression in BrainCloud database. SNP 
rs1150711 is absent in the NCBI eQTL browser, we there-
fore queried rs2859365. Again, we found the only eQTL 
gene for rs2859365 is ZNF323 (P  =  2.93 × 10–8). These 
results suggest that ZNF323 may represent the most 
possible biological candidate gene behind rs1150711 (or 
rs2859365).
Bioinformatic Analysis of rs1150711 and Functional 
Prediction
To explore the potential mechanisms underlying the 
significant association between rs1150711 and ZNF323 
expression, we performed bioinformatic analyses. Recent 
studies showed that the chromatin interaction plays an 
important role in regulating gene expression.38,59 We 
therefore extracted the chromatin interaction data gener-
ated by Dixon et al (http://yuelab.org/hi-c/).38 We found 
there was chromatin interaction (topologically associated 
domains [TAD]) between the genomic region contain-
ing rs1150711 and its neighboring regions (supplemen-
tary figure S4). However, due to the fact that TAD spans 
about 700 kb and there are many genes in this region, 
more work is needed to elucidate if  rs1150711 can directly 
regulate the expression of ZNF323. We also utilized the 
ENCODE data to predict the potential functional conse-
quences of rs1150711 using Regulome DB (http://www.
regulomedb.org).39 We found that SNP rs1150711 have 
RegulomeDB score of 3a (supplementary figure S5), 
indicating that at least three lines of evidence support 
this SNP is functional. First, ChIP-seq data revealed that 
rs1150711 is located in a transcription factor (TF) binding 
region. TFs MAFK and RFX3 can bind to the genomic 
sequence containing rs1150711. Second, rs1150711 is 
located in a well-defined motif  region (Evi-1) and nucleo-
tide substitution at rs1150711 may affect TFs binding. 
Third, DNase-seq data showed that rs1150711 is located 
in DNase peaks. These results implied that rs1150711 
may have potential functional role in regulating ZNF323 
expression. However, more work is needed to test whether 
SNP rs1150711 is functional.
Significant Downregulation of ZNF323 in the Frontal 
Cortex and Hippocampus of Schizophrenia Patients
Sherlock integrative analysis revealed that the expression 
changes of ZNF323 may contribute to schizophrenia 
risk. To further validate this, we tested whether ZNF323 
expression in the frontal cortex and/or hippocampus is 
dysregulated in schizophrenia patients using the SNCID 
data.26 We found that ZNF323 expression is significantly 
downregulated in schizophrenia patients compared with 
normal controls in both frontal cortex (P  =  .023) and 
hippocampus (P  =  .00376) (figure  2). Interestingly, we 
noticed that the T allele of rs1150711, which is associ-
ated with lower ZNF323 expression in PFC and hip-
pocampus, is significantly enriched in schizophrenia 
cases (table 3). We further examined if  other neighbor-
ing genes of rs1150711 are differentially expressed in 
schizophrenia cases and controls using the data from the 
SNCID.26 Genes located in a 100-kb window surround-
ing rs1150711 were examined. In addition to ZNF323, six 
genes (ZNF192, ZNF193, ZNF187, ZNF427, NKAPL, 
PGBD1) are located in the 100-kb window surrounding 
rs1150711. We found that these genes did not show dif-
ferential expression in frontal cortex of schizophrenia 
cases and controls. Collectively, these findings provide 
further evidence that support the potential involvement 
of ZNF323 expression in schizophrenia susceptibility.
Pleiotropic Analyses for ZNF323
We explored whether ZNF323 is also associated with 
other human traits. A  query of the NHGRI GWAS 
catalog (accession date April 01, 2014)  for ZNF323 (or 
its alias names) revealed that the only entry listed was a 
GWAS for lung function.60 The trait(s) analyzed in this 
GWAS were the ratio of “forced expiratory volume in 1 
second (FEV1)” to “forced vital capacity (FVC)” as well 
as FEV1. The strongest association for a SNP in ZNF323 
in the aforementioned GWAS was rs6903823 (FEV1/
FVC: P = .001 for joint meta-analysis of all stages; FEV1: 
P = 2.18 × 10−10) (supplementary table S3). Analyses of 
genetic correlation between rs6903823 and rs2859365/
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rs1150711 based on 1000 Genomes data (phase 1)44 in 
CEU-revealed moderate LD (r2: 0.480 and 0.448, respec-
tively; D′: 0.871 and 1.000, respectively). We observed 
evidence for association of rs1150711 in the aforemen-
tioned lung function GWAS (FEV1: P  =  6.62 × 10
–5) 
(supplementary table S3). The association for rs6903823 
in the PGC1+SWE schizophrenia GWAS was signifi-
cant (P  =  2.29 × 10−10). It is of note that in both SNPs 
(rs1150711 and rs6903823) the risk allele for schizophre-
nia (T and A, respectively) shows a protective effect in the 
lung function GWAS60 (supplementary table S3).
Encouraged by this finding and the observation that 
ZNF323 is expressed in the lung, we tested whether our 
eSNPs for ZNF323 in the brain also showed association 
with ZNF323 expression in the lung. Based on 119 indi-
viduals included in the GTEx dataset,25 we found signifi-
cant association for both rs2859365 and rs1150711 with 
ZNF323 expression in the lung (P = .008 and P = 9 × 10–
5) (supplementary figure S6). Furthermore, we observed 
that for both markers the carriers of the schizophrenia 
risk alleles (rs2859365:A; rs1150711:T), ie, carriers of 
the allele that confers protective effects to lung function, 
did show a reduced expression of ZNF323 (in brain and 
lung) (supplementary figure S6).
Evidence for simultaneous association of genetic varia-
tion with different traits (pleiotropy) is sometimes based 
on confounding factors (hidden factors associated with 
the genetic variation and at the same time with the seem-
ingly pleiotropic traits). Utilizing results from the TAG 
GWAS on smoking behavior (see “Methods” section of 
this manuscript for the analysis rationale), we found no 
evidence for association of our top eSNPs with smoking 
behavior as a potential confounding factor (for rs2859365 
and rs1150711, all corrected P-value > .05; supplemen-
tary table S4).
Population Genetics Analyses for rs1150711
Based on our findings for schizophrenia and lung 
function, we investigated the evolutionary pattern of 
rs1150711 and ZNF323 in human populations using 
population genetic analyses. We first detailed the dis-
tribution of  rs1150711 allele frequency in worldwide 
populations using data from the HGDP47 and the 
1000 Genomes project.44 We found that the frequency 
of  the T allele of  rs1150711 (derived and risk allele) 
is highly variable in world-wide populations ranging 
from lower frequencies in most African populations 
to higher frequencies in other populations (figure 3). 
At the extremes we found that rs1150711 is fixed 
(either for the ancestral or the derived allele) in some 
populations (figure  3). Fst analysis also indicates a 
high degree of  population differentiation in African, 
European, and Asian populations for rs1150711 
(Fst = 0.44).
The dramatic differences in allelic frequency strongly 
suggested that rs1150711 might have experienced recent 
positive selection in human populations. To test this, we 
calculated the iHS45 of rs1150711 in world populations. 
The iHS analysis (figure  4A and supplementary table 
S5) revealed that the derived allele of rs1150711 (T) has 
experienced strong recent positive selection in Europeans 
(CEU; iHS = −2.034, P < .05) and Asians (iHS = −2.206, 
P < .05), while we did not observe evidence for signifi-
cant positive selection in Africans (iHS = -0.617, P > .05). 
This finding was supported by the EHH41 analyses across 
all three studied populations, the haplotypes carrying the 
T allele (derived allele, is also the risk allele) of rs1150711 
decay slower for the derived alleles than for the ancestral 
alleles (figures 4B, 4E, and 4H).
We further plotted haplotype bifurcation diagrams41 
for both alleles at rs1150711 (figures 4C, 4D, 4F, 4G, 4 
Fig. 2. ZNF323 is significantly downregulated in the frontal cortex and hippocampus of schizophrenia patients. (A) Compared with healthy 
controls, ZNF323 expression was significantly downregulated in frontal cortex of schizophrenia patients. (B) Expression of ZNF323 was 
significantly decreased in hippocampus of schizophrenia cases. BP, patients with bipolar disorder, Schiz., patients with schizophrenia.
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I, and 4J). Consistent with our EHH and iHS results, 
we found that the bifurcation of haplotypes containing 
the derived allele (T) was slower in contrast to haplo-
types with the ancestral allele (C). Haplotypes carrying 
the derived allele (T) of rs1150711 have unusual high 
EHH and high population frequency, indicating that 
recent positive selection operated on the derived allele 
and as a result led to a faster increase in its frequency 
in the human population when compared with a model 
under neutral evolution. Further analyses using haplot-
ter45 confirmed our findings (supplementary figure S7). 
Collectively, these results indicate that the derived allele 
of rs1150711 (T) has experienced recent positive selection 
in human populations.
We also explored the recent positive selection on 
rs2859365. Consistent with the results of  rs1150711, 
iHS analysis revealed that the risk allele of  rs2859365 
(A allele) might have experienced significant recent 
positive selection in Europeans (iHS  =  −2.023, P < 
.05). Nevertheless, we did not observe significant 
recent positive selection in Chinese and African pop-
ulations (iHS  =  −0.547 and −1.051, respectively, P 
> .05) (supplementary table S6 and supplementary 
figure S8). The results of  EHH showed similar pat-
terns (supplementary table S6 and supplementary fig-
ure S8). Tajima’s D, Fu and Li’s D and F tests, and 
Fay and Wu’s H test indicated that the evolution of 
ZNF323 did not deviate from neutrality significantly 
(supplementary table S7), which further suggesting 
that the positive selection on rs1150711 and ZNF323 
is a relatively recent event.
It is conceivable that the positive selection of the 
derived allele of rs1150711 (T) in the human populations 
was driven by other SNPs in LD with rs1150711 (“genetic 
Fig. 3. Global distribution of the rs1150711 risk allele (T allele) in world populations. (A) Global distribution of the risk allele (T allele) 
of rs1150711 in world populations. The frequency of the risk allele is highly variable in world populations. For example, it is absent in 
San population from Africa (black arrow), nevertheless, the risk allele (T allele) is completely fixed (frequency = 1.0) in Surui population 
from Brazil (red arrow). (B) Allele frequency distribution of the risk allele (T allele) of rs1150711 in four continental populations 
from the 1000 genomes projects. The frequency of the risk allele of rs1150711 is low in African populations. However, the risk allele is 
prevalent in other populations, including European, Asian, and American populations.
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hitchhiking”). To test this hypothesis we utilized the 
CMS method46 and found that rs1150711 has the highest 
score among the 11 brain eSNPs for ZNF323 that were 
identified in the BrainCloud data (figure 4K), suggesting 
that rs1150711 is likely the site that drives the positive 
selection.
As our focus is ZNF323 in this study, therefore, we did 
not follow other top predicted genes. The reasons that we 
focused on ZNF323 are as follows: (1) Sherlock integra-
tion analysis revealed that ZNF323 showed the most sig-
nificant association with schizophrenia (with the lowest 
LBF). (2) We noticed that among the top four predicted 
genes, only the supporting SNP (rs2859365) of ZNF323 
is located near the ZNF323 gene (cis eQTL). Generally 
speaking, cis eQTL is more likely to be functional. 
Nevertheless, other genes are also deserved to be investi-
gated in the future.
Discussion
Though genetic studies have revealed multiple promising 
risk variants that show robust association with schizophre-
nia, how these risk variants contribute to schizophrenia 
susceptibility remains largely unknown. Given that most 
of the identified risk variants are located in noncoding 
regions, it is likely that these risk variants alter the expres-
sion of schizophrenia-associated genes rather than pro-
tein function. Our study systematically integrated brain 
eQTL data18 and genetic association findings from a large 
GWAS of schizophrenia (PGC1 + SWE, with a total of 
32 143 subjects).11 Our findings revealed that ZNF323 is 
significantly associated with schizophrenia. We validated 
the association between eSNPs of ZNF323 (rs2859365 
and rs1150711) at both the gene expression level and at 
the level of the association with schizophrenia. It should 
Fig. 4. Recent positive selection of rs1150711 risk allele in human populations. (A) iHS value of the 11 single nucleotide polymorphisms 
(SNPs) that showed significant association with schizophrenia and ZNF323 expression in Europeans. (B, C, D) extended haplotype 
homozygosity (EHH) and haplotype bifurcation plots of rs1150711 in Han Chinese. (E, F, G) EHH and haplotype bifurcation plots of 
rs1150711 in Europeans. (H, I, J) EHH and haplotype bifurcation plots of rs1150711 in Africans. (B, E, H) Decay of EHH for the risk 
allele (T allele) of rs1150711 in three representative world populations (B, CHB, Han Chinese; E, CEU, Europeans; H, YRI, Africans) 
over physical distance. In each population, the decay of haplotype homozygosity for the risk allele (red) occurs much more slowly than 
for the protective allele (blue), indicating strong positive selection acting on haplotypes containing this risk allele. (C, D, F, G, I, J) 
Haplotype bifurcation graphs show that the bifurcation of haplotypes is also slower for the risk allele (T allele) of rs1150711 (C, F, I) 
compared with the protective allele (C allele) (D, G, J). In all of studied populations (CHB, CEU, and YRI), bifurcation of haplotypes 
for the risk allele (T allele) of rs1150711 is significantly lower than for the protective allele (C allele). The haplotype thicknesses represent 
the haplotype frequency. Haplotypes with unusually high EHH and a high population frequency (thicknesses) suggest the presence of 
recent positive selection that drives rapid increase in frequency of new variants or haplotypes in the population. Usual long and thick 
haplotypes are observed for the risk allele of rs1150711, but not for the protective allele, indicating recent positive selection of the 
risk allele. (K) Composite of multiple signals (CMS) score of the 11 SNPs that showed significant association with schizophrenia and 
ZNF323 expression in Europeans. rs1150711 (marked by red) has the highest CMS score, suggesting it is likely represents the variant that 
under positive selection. The CMS score of rs9461446 and rs9461448 was not available.
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be noted that our replication results for association of 
rs2859365 and rs1150711 with schizophrenia are in line 
with the findings of a recently published study (“PGC2 
SCZ”) that reported schizophrenia-association of 108 
genetic loci.61 Although our own results unfortunately 
could only provide moderate further evidence for asso-
ciation, “PGC2 SCZ” put the evidence for association 
of rs2859365 and rs1150711 beyond reasonable doubt 
(1.68 × 10–11 and 2.62 × 10–13). In fact, the P values of 
rs2859365 and rs1150711 were steadily diminished with 
the increase of sample size (supplementary table S8), 
strongly suggesting that rs2859365 and rs1150711 are 
authentic risk variants for schizophrenia. Please note 
that all but one (“Danish2”) of the studies used for our 
analyses were included in the bigger “PGC2 SCZ” study. 
We also performed Sherlock integrative analysis using the 
PGC2 SCZ data set and found that ZNF323 still ranked 
in the top 5, which further suggests that ZNF323 may 
represent an authentic candidate gene.
It should be noted that the P value of rs2859365 did not 
reach a significant level and P value of rs1150711 showed 
marginally significant association (P = .037) with schizo-
phrenia in the combined replication samples. Following 
two reasons may lead to these results: First, compared 
with other replication samples, we noticed that the Danish 
sample 1 has a different risk allele, which increased the 
P value when all of the replication samples were com-
bined. In fact, when the Danish sample 1 was excluded, 
rs2859365 and rs1150711 showed significant associations 
with schizophrenia in the replication samples. Second, 
considering that the sample size of the combined replica-
tion samples is still relatively small (N = 6353 cases) and 
the association trend (the affect allele) in the combined 
replication samples is same as the discovery sample, we 
may obtain a more significant P value if  the sample size 
is increased in the replication stage.
ZNF323 (also known as ZSCAN31) encodes SCAN/
(Cys)2(His)2 zinc-finger TF that plays an active role in 
human embryonic development.62 Expression analysis 
revealed that ZNF323 is extensively expressed in human 
tissues, including lung, liver, kidney, brain, heart, and 
pancreas,62 suggesting that is may be involved in the 
development of multiple embryonic organs (including 
brain). Recent studies reveal the important role of zinc-
finger TFs in schizophrenia. For example, ZNF804A, the 
first identified gene that showed genome-wide significant 
association with schizophrenia,63 also encodes a zinc fin-
ger protein. In addition to schizophrenia, significant asso-
ciation between ZNF804A and bipolar disorder also has 
been reported.64 These lines of evidence suggest that zinc-
finger TF may play a pivotal role in psychiatric disorders.
ZNF323 is located on the MHC region. This region 
on chromosome 6 is known to harbor a large number of 
disease associated variants for traits such as mental dis-
orders (eg, schizophrenia),10 traits related to immune pro-
cesses (eg, rheumatoid arthritis),65 and many others.66,67 
Due to the extended LD in this region, pinpointing the 
genes of  interest remained a challenge in most of  the 
studies. Our integrated analysis design potentially could 
help to identify more disease relevant genes in the MHC 
region. Although eQTL studies in general suffer from 
similar limitations that GWA studies do (large amount 
of  correlated measurements), integrating several lay-
ers of  gene expression with genetic data and other data 
might help to pinpoint disease associated genes. In our 
study only gene expression of  ZNF323 was affected 
by all the 11 eSNPs in the brain (table  2). Moreover, 
we found evidence for a significantly reduced ZNF323 
expression in brains of  schizophrenia patients (in brain 
regions relevant to schizophrenia). More importantly, 
we noted that lower ZNF323 expression-associated 
alleles at rs2859365 and rs1150711 were enriched in 
schizophrenia cases (OR  =  1.082 and 1.105, respec-
tively). In addition to ZNF323, several other genes were 
also be identified by Sherlock (table 1). We noticed that 
EIF4A2 was reported to be downregulated in brains 
(anterior temporal lobe) of  schizophrenia patients.68 In 
addition, genetic variants in LSAMP showed significant 
association with schizophrenia69 and several other men-
tal disorders, including major depressive disorder and 
panic disorder,70 and male suicide.71 These lines of  evi-
dence strongly suggest the validity of  Sherlock in identi-
fying disease susceptibility genes.
Not only did we identify a new potential risk gene for 
schizophrenia but also we could find evidence for recent 
positive selection for rs1150711 and thus potentially pro-
vide a possible explanation to the evolutionary enigma of 
schizophrenia.4 Although in general this is of no surprise 
for genetic variation located in the MHC region,11 we were 
also able to link the evidence for recent positive selection 
with a reasonable candidate mechanism that could have 
provided compensatory advantage. Gene expression of 
ZNF323 in brain and lung is reduced as a consequence of 
the presence of the derived allele of rs1150711, which at 
the same time confers risk to schizophrenia and provides 
a protective effect on lung function. Considering that the 
protective allele on lung function (rs1150711-T) has expe-
rienced positive selection in Europeans, it is possible that 
lung function (measured as FEV1 and FCV) may show 
difference among different populations. Interestingly, one 
study showed that compared with European children, the 
lung function (FEV1 and FVC) of African and Asian 
children were significantly lower.72 These results suggest 
that lung function might have experienced positive selec-
tion in Europeans. It is of note that the protective effect 
on lung function is probably only one of multiple mecha-
nisms that could have helped the risk allele of rs1150711 
to escape extinction from the human gene pool (as a 
consequence of its involvement in schizophrenia sus-
ceptibility). Further work is warranted to investigate the 
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